Latest Breaking News On - Conditional marketing authorization - Page 2 : comparemela.com

Epcoritamab Receives UK Approval for R/R DLBCL After 2 Prior Lines of Therapy

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted conditional marketing authorization to epcoritamab-bysp monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapy.

United kingdomChris foxUniversity of nottinghamHealthcare products regulatory agencyNottingham university hospitalsSchool of medicineEuropean commissionHealthcare products regulatoryMedicines and healthcare products regulatory agencyEpcoritamab byspDiffuse largeb cell lymphomaConditional marketing authorizationEpcore nhl 1 trial

180 Life Sciences Corp (ATNF) Receives Written Scientific Response from the UK MHRA Following August Meeting

180 Life Sciences Corp (ATNF) Receives Written Scientific Response from the UK MHRA Following August Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomLife sciences corpCompany phaseEuropean medicines agencyDrug administrationHealthcare products regulatory agencySciences corpMarketing authorizationConditional marketing authorizationMarketing authorisation

Biophytis S A : Interim Financial Report issued by the registrant on September 27, 2023 - Form 6-K -September 27, 2023 at 05:04 pm EDT

French public limited company with a Board of Directors with share capital of €4,267,706.99 Registered office: 14 Avenue de l Opéra - 75001 PARIS Paris Commercial Register .

United statesUnited kingdomFrance generalIntsel chimosClaude allaryNadine coulmJean marianiEuropean medicines agencyInternational accounting standardsResearch tax creditInternational financial reporting interpretations committeeBiophytis inc united statesCompany board of directors onCompanies registryDevelopment of sarconeosInternational accounting standards board

Ligand s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head.

Todd davisDeric dubeLigand pharmaceuticals incorporatedCommittee for medicinal products human useGilead sciencesLigand pharmaceuticalsTravere therapeutics incEuropean medicines agencyBaxter internationalExchange commissionTravere therapeuticsNew drug applicationConditional marketing authorizationMedicinal productsHuman usePrivate securities litigation reform act

Travere Therapeutics Announces Confirmatory Data from the Phase 3 Protect Study of Filspari Demonstrating Long-Term Kidney Function Preservation in Iga Nephropathy; Narrowly Missing Egfr Total Slope Endpoint Versus Active Control, Irbesartan

Travere Therapeutics, Inc. announced topline two-year confirmatory secondary endpoint results from the Company?s pivotal head-to-head Phase 3 PROTECT Study of FILSPARI® in IgA nephropathy versus.

European medicines agencyCommittee for medicinal products human useTravere therapeutics incTravere therapeuticsNew drug applicationConditional marketing authorizationMedicinal productsHuman use